Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.

乌斯特基努马 医学 克罗恩病 内科学 临床试验 随机对照试验 疾病 随机化 外科 物理疗法
作者
Silvio Danese,Severine Vermeire,Geert D'Haens,Julian Panés,Axel Dignass,Fernando Magro,Maciej Nazar,Manuela Le Bars,Marjolein Lahaye,Lioudmila Ni,Ivana Bravata,Frederic Lavie,Marco Daperno,Milan Lukáš,Alessandro Armuzzi,Mark Löwenberg,Daniel R Gaya,Laurent Peyrin-Biroulet
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:7 (4): 294-306
标识
DOI:10.1016/s2468-1253(21)00474-x
摘要

A treat-to-target strategy, in which strictly defined treatment targets facilitate decision making in clinical practice, is advocated as an optimised management approach for some chronic disorders. The aim of the STARDUST trial was to assess whether a treat-to-target strategy with early endoscopy, regular biomarker and clinical symptom monitoring, and dose intensification for persistent inflammatory activity, was more successful in achieving endoscopic improvement at week 48 than a clinically driven maintenance strategy in patients with moderate-to-severe active Crohn's disease receiving ustekinumab.This open-label, multicentre, randomised phase 3b trial included adults with active, moderate-to-severe Crohn's disease (Crohn's Disease Activity Index [CDAI] 220-450 and Simple Endoscopic Score in Crohn's Disease [SES-CD] ≥3) for whom conventional therapy or one biologic therapy, or both, had failed. Patients received intravenous ustekinumab approximating 6 mg/kg at baseline and subcutaneous ustekinumab 90 mg at week 8. At week 16, patients with a CDAI improvement of 70 or more points from baseline were randomly assigned (1:1) to receive standard-of-care or treat-to-target maintenance treatment through week 48. Randomisation was balanced by using randomly permuted blocks and was stratified by biologic history status and baseline SES-CD score. All patients who signed informed consent, who were not screening failures, and who received at least one dose of study treatment were included in week 16 analyses. All patients included in week 16 analyses and randomly assigned to one of the maintenance treatment regimens were included in the week 48 efficacy and safety analyses (ie, on an intention-to-treat basis). Patients assigned to the treat-to-target arm received ustekinumab every 12 weeks or every 8 weeks based on SES-CD improvement from baseline and could escalate to every 4 weeks through week 48 if prespecified targets were missed. Patients assigned to the standard-of-care arm received ustekinumab every 12 weeks or every 8 weeks; those receiving treatment every 12 weeks could escalate per European labelling. The primary efficacy endpoint was endoscopic response at week 48 (SES-CD score ≥50% decrease from baseline), analysed by non-responder imputation. This trial is registered at ClinicalTrials.gov, NCT03107793, and is active but not recruiting.498 patients received standard induction treatment, of whom 440 were randomly assigned to the treat-to-target group (n=219) or the standard-of-care group (n=221). At week 48, there was no significant difference in endoscopic response (83 [38%] of 219 patients vs 66 [30%] of 221 patients; p=0·087), endoscopic remission (25 [11%] vs 32 [15%]; p=0·334), mucosal healing (31 [14%] vs 37 [17%]; p=0·449), and clinical remission (135 [62%] vs 154 [70%]; p=0·072) between the two groups; clinical response was significantly lower in the treat-to-target group than in the standard-of-care group (149 [68%] vs 172 [78%]; p=0·020). Other endoscopic, clinical, and biomarker outcomes were generally not significantly different between groups. The most commonly reported treatment-emergent adverse events were nasopharyngitis (29 [13%] of 219 patients in the treat-to-target group vs 29 [13%] of 221 patients in the standard-of-care group), abdominal pain (23 [11%] vs 19 [9%]), arthralgia (24 [11%] vs 19 [9%]), and headache (24 [11%] vs 21 [10%]).Timely escalation of ustekinumab therapy for patients with Crohn's disease, based on early endoscopic response, clinical symptoms, and biomarkers, did not result in significantly better endoscopic outcomes at week 48 than symptom-driven decisions alone. Future studies need to confirm if some subgroups of patient might benefit from a treat-to-target strategy with ustekinumab.Janssen-Cilag.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
不扯先生完成签到,获得积分10
5秒前
5秒前
qin发布了新的文献求助10
6秒前
捷克完成签到,获得积分20
8秒前
小蘑菇应助美丽的友卉采纳,获得10
11秒前
11秒前
13秒前
13秒前
14秒前
liziqqq完成签到,获得积分10
14秒前
14秒前
15秒前
共享精神应助刘云采纳,获得10
17秒前
17秒前
17秒前
20010103zjl完成签到 ,获得积分20
17秒前
AQ发布了新的文献求助10
18秒前
18秒前
19秒前
高歌发布了新的文献求助20
19秒前
pat完成签到,获得积分10
19秒前
Orange应助HYW采纳,获得10
20秒前
重生之我是院士完成签到,获得积分10
22秒前
Buaa_Jack应助Jion采纳,获得10
22秒前
柏林发布了新的文献求助10
22秒前
Sam完成签到,获得积分10
22秒前
爱听歌的忆翠关注了科研通微信公众号
23秒前
23秒前
无心的行云完成签到,获得积分10
24秒前
24秒前
李健应助科研通管家采纳,获得10
25秒前
田様应助科研通管家采纳,获得10
25秒前
研友_VZG7GZ应助十八冠六采纳,获得10
25秒前
科目三应助科研通管家采纳,获得10
25秒前
YXYWZMSZ发布了新的文献求助10
25秒前
25秒前
充电宝应助科研通管家采纳,获得10
25秒前
25秒前
香蕉觅云应助科研通管家采纳,获得10
25秒前
高分求助中
Manual of Clinical Microbiology, 4 Volume Set (ASM Books) 13th Edition 1000
Sport in der Antike 800
De arte gymnastica. The art of gymnastics 600
Berns Ziesemer - Maos deutscher Topagent: Wie China die Bundesrepublik eroberte 500
Stephen R. Mackinnon - Chen Hansheng: China’s Last Romantic Revolutionary (2023) 500
Sport in der Antike Hardcover – March 1, 2015 500
Boris Pesce - Gli impiegati della Fiat dal 1955 al 1999 un percorso nella memoria 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2421509
求助须知:如何正确求助?哪些是违规求助? 2111313
关于积分的说明 5344298
捐赠科研通 1838822
什么是DOI,文献DOI怎么找? 915410
版权声明 561179
科研通“疑难数据库(出版商)”最低求助积分说明 489550